Cited by 167Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

Open access

Sutani, A, Nagai, Y, Udagawa, K, Uchida, Y, Koyama, N, Murayama, Y, Tanaka, T, Miyazawa, H, Nagata, M, Kanazawa, M, Hagiwara, K, Kobayashi, K·2006·British Journal of Cancer

DOI 10.1038/sj.bjc.6603466PMC PMC2360739

Open this paper in CoChat — free account Open PDF

Abstract

This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients having EGFR mutations were given gefitinib 250 mg daily as the second treatment after chemotherapy. Poor PS patients omitted chemotherapy. Of 107 consecutive patients enrolled, samples from 100 patients were informative, and EGFR mutations were observed in 38 patients. Gefitinib was given to 27 patients with EGFR mutations, and the response rate was 78% (one complete response and 20 partial responses; 95% confidence interval: 58-93%). Median time to progression and median survival time (MST) from gefitinib treatment were 9.4 and 15.4 months, respectively. Grade 3 hepatic toxicity and skin toxicity were observed in one patient each. There were significant differences between EGFR mutations and wild-type patients in response rates (78 vs 14%, P = 0.0017), and MST (15.4 vs 11.1 months, P = 0.0135). A Cox proportional hazards model indicated that negative EGFR mutation was a secondary prognostic factor (hazards ratio: 2.259, P = 0.036). This research showed the need for screening for EGFR mutations in NSCLC patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6603466

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 940
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 696
Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
Pao, W. J., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 637
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 101–165 of 165

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
Okamoto, I., Yoshida, & Kaneda (2013) · Cancer Management and Research · doi:10.2147/cmar.s32973 · Cited by 21
Management of Patients with Advanced Non-Small Cell Lung Cancer
Triano, L. R., Deshpande, H. A., & Gettinger, S. N. (2010) · Drugs · doi:10.2165/11532200-000000000-00000 · Cited by 21
Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer
Mok, T. S. K., Lee, K., & Leung, L. K. S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.010 · Cited by 20
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib
Fujiwara, Y., Kiura, K., Toyooka, S., Hotta, K., Tabata, M., Takigawa, N., Soh, J., Tanimoto, Y., Kanehiro, A., Kato, K., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.018 · Cited by 20
The search for improved systemic therapy of non-small cell lung cancer—What are today's options?
Früh, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.020 · Cited by 20
Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)
Usui, K., Yokoyama, T., Naka, G., Ishida, H., Kishi, K., Uemura, K., Ohashi, Y., & Kunitoh, H. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz023 · Cited by 19
PharmGKB summary
Hodoğlugil, U., Whirl‐Carrillo, M., Hebert, J. M., Karachaliou, N., Rosell, R., Altman, R. B., & Klein, T. E. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283655091 · Cited by 18
Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan
Okamoto, I. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0754-y · Cited by 18
Droplet digital polymerase chain reaction assay and peptide nucleic acid‐locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T‐cell lymphoma
Nuhat, S. T., Sakata‐Yanagimoto, M., Komori, D., Hattori, K., Suehara, Y., Fukumoto, K., Fujisawa, M., Kusakabe, M., Matsue, K., Wakamatsu, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13557 · Cited by 17
E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib
Miyanaga, A., Gemma, A., Ando, M., Kosaihira, S., Noro, R., Minegishi, Y., Kataoka, K., 奈良, 道., Okano, T., Miyazawa, H., et al. (2008) · Oncology Reports · doi:10.3892/or.19.2.377 · Cited by 17
Self-citation
Impact of biomarkers on non-small cell lung cancer treatment
Toschi, L., & Cappuzzo, F. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0132-y · Cited by 16
Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
Matsuura, S., Inui, N., Ozawa, Y., Nakamura, Y., Toyoshima, M., Yasuda, K., Yamada, T., Shirai, T., Suganuma, H., Yokomura, K., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr079 · Cited by 16
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan
Lin, C., Hsu, K.-H., Chang, S., Tsou, H., Sheehan, J. P., Sheu, M., & Pan, H.-C. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0431-7 · Cited by 15
The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
Huang, W.-L., Wei, F., Wong, D. T., Lin, C., & Su, W. (2015) · BioMed Research International · doi:10.1155/2015/340732 · Cited by 14
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
Reck, M. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.63 · Cited by 14
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
Yoshida, K., Yatabe, Y., Jangchul, P., Ogawa, S., Park, J. Y., Shimizu, J., Horio, Y., Matsuo, K., Mitsudomi, T., & Hida, T. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0685-2 · Cited by 13
Gefitinib for non-small-cell lung cancer treatment
D’Incecco, A., & Cappuzzo, F. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.617738 · Cited by 13
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
Köhler, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00009 · Cited by 13
Good Clinical Response to Erlotinib in a Patient With Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21
Masago, K., Miura, M., Toyama, Y., Togashi, Y., & Mishima, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0216 · Cited by 13
Direct Comparison of 3 PCR Methods in Detecting EGFR Mutations in Patients with Advanced Non–Small-Cell Lung Cancer
Ikeda, T., Nakamura, Y., Yamaguchi, H., Tomonaga, N., Doi, S., Nakatomi, K., Iida, T., Motoshima, K., Mizoguchi, K., Nagayasu, T., et al. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.008 · Cited by 12
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study
Katayama, T., Matsuo, K., Kosaka, T., Sueda, T., Yatabe, Y., & Mitsudomi, T. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2010.07.002 · Cited by 11
Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
Ohara, S., Ushijima, T., Gunji, M., Tanai, C., Tanaka, Y., Noda, H., Horiuchi, H., & Usui, K. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-64 · Cited by 11
The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations
Taniguchi, Y., Matsumoto, Y., Furukawa, R., Ohara, S., & Usui, K. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1233-8 · Cited by 11
Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
Baba, K., Fujita, T., Tasaka, S., & Fujii, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164020 · Cited by 11
The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer
Yamada, N., Oizumi, S., Asahina, H., Shinagawa, N., Kikuchi, E., Kikuchi, J., Sakakibara‐Konishi, J., Tanaka, T., Kobayashi, K., Hagiwara, K., et al. (2012) · Oncology · doi:10.1159/000338327 · Cited by 11
Self-citation
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
Masago, K., Togashi, Y., Fukudo, M., Terada, T., Irisa, K., Sakamori, Y., Fujita, S., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Case Reports in Oncology · doi:10.1159/000310830 · Cited by 11
Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non–small cell lung cancer patients
Masago, K., Fujita, S., Kim, Y. H., Ichikawa, M., Hatachi, Y., Fukuhara, A., Nagai, H., Irisa, K., Mio, T., & Mishima, M. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.06.025 · Cited by 11
Translation of pharmacogenetic knowledge into cancer therapeutics.
Yong, W. P., & Innocenti, F. (2007) · PubMed · Cited by 11
[Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer].
Fang, Q., Zhang, L., Wang, S., & Ou, W. (2011) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2011.06.07 · Cited by 8
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
Clinical utility of the Oncomine Dx Target Test multi‐CDx system and the possibility of utilizing those original sequence data
Saito, A., Terai, H., Kim, T. J., Emoto, K., Kawano, R., Nakamura, K., Hayashi, H., Takaoka, H., Ogata, A., Kinoshita, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7077 · Cited by 7
Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
Vincenten, J. P. L., Smit, E. F., Grünberg, K., Postmus, P. E., Snijders, P. J. F., Lissenberg-Witte, B. I., Heideman, D. A. M., & Thunnissen, E. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.005 · Cited by 7
Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy
Masago, K., Fujita, S., Togashi, Y., Kim, Y. H., Hatachi, Y., Fukuhara, A., Nagai, H., Sakamori, Y., Mio, T., & Mishima, M. (2011) · Clinical Lung Cancer · doi:10.3816/clc.2011.n.008 · Cited by 7
Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide
Reiki, I., Fujii, H., Miura, T., Yukiko, F., & Tajima, K. (2012) · Personalized Medicine Universe · doi:10.1016/j.pmu.2012.05.006 · Cited by 7
Targeted therapies in non-small cell lung cancer
Kyle, F. J. (2008) · Cancer Imaging · doi:10.1102/1470-7330.2008.0027 · Cited by 6
EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy
Kim, Y. H., Masago, K., Togashi, Y., Sakamori, Y., Okuda, C., Mio, T., & Mishima, M. (2011) · Oncology Letters · doi:10.3892/ol.2011.240 · Cited by 6
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
Karachaliou, N., & Rosell, R. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s50671 · Cited by 6
3) Non-small Cell Lung Cancer
Kobayashi, K. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.2520 · Cited by 5
Self-citation
A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy
Zheng, X., Liu, G., Wang, S., Zhang, Y., BAO, W., Deng, D., MAO, W., & Fang, M. (2014) · Oncology Letters · doi:10.3892/ol.2014.2386 · Cited by 5
New targeted therapies for non-small-cell lung cancer
Metro, G., & Cappuzzo, F. (2009) · Therapy · doi:10.2217/thy.09.5 · Cited by 5
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment — First-line therapy
Gridelli, C., Rossi, A., & Maione, P. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70171-x · Cited by 5
QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review
Khokhar, B., Chiang, B., Iglay, K., Reynolds, K. R., Rodriguez‐Ormaza, N., Spalding, W. M., & Freedland, E. S. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.02.005 · Cited by 4
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Govindan, R. (2010) · Biologics · doi:10.2147/btt.s4144 · Cited by 4
Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib
Kiura, K., Takigawa, N., & Segawa, Y. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_21 · Cited by 3
[Association between the epidermal growth receptor status and the efficacy of first-line chemotherapy in patients with advanced non-small cell lung cancer].
Qin, N., Zhang, Q., Wang, J., Zhang, H., Gu, Y., Yang, X., Li, X., Lv, J., Wu, Y., Nong, J., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.03.02 · Cited by 2
Guide to Targeted Therapies: EGFR mutations in NSCLC
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3
Ethnic variation in response to EGFR inhibitors
Loong, H. H.-F., Wei, J., & Mok, T. S. K. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.04.003 · Cited by 1
Targeted Therapies for Non-small-Cell Lung Cancer
Metro, G., & Crinò, L. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_4 · Cited by 1
5. New Findings of Drug-induced Lung Injury
Kanazawa, M. (2008) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.97.105c · Cited by 1
Self-citation
The squamous situation: Ancillary testing in pulmonary squamous cell carcinoma and implications for cytology laboratories
Monaco, S. E. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21813 · Cited by 1
5. New Findings of Drug-induced Lung Injury
Kanazawa, M. (2008) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.97.2250 · Cited by 1
Self-citation
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv471.20 · Cited by 1
Genomics and Molecular Profiling of Lung Cancer
Xu, Z. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00012-8 · Cited by 1
Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
Naito, Y., & Goto, K. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2122
Development of PNA-based systems for food safety and molecular biology
Tonelli, A. (2010) · DSpaceUnipr (University of Parma)
A case of long-term survival of gefitinib-induction therapy for advanced N2-multistation lung cancer without epidermal growth factor receptor gene mutation
Ayabe, T., Shimizu, T. M., Tomita, M., Hara, M., & Onitsuka, T. (2012) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.19.62
Pharmacogenomics: challenges in promoting its clinical usage
Tsuruo, T. (2008) · Folia Pharmacologica Japonica · doi:10.1254/fpj.132.31
Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials
Aydıner, A. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.324060
Gefitinib: Re-Emerging from the Shadows
Martin, P., Owen, S. P., & Leighl, N. B. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.42
Reanalysis of the EGFR Mutation Status in Non-small Cell Lung Cancer Patients Without an EGFR Mutation Treated with Erlotinib
Ohara, S., Ushijima, T., Tanai, C., Tanaka, Y., Noda, H., Horiuchi, H., & Usui, K. (2013) · Haigan · doi:10.2482/haigan.53.324
Place des thérapeutiques biologiques ciblées
Wislez, M., & Cadranel, J. L. (2008) · ONCOLOGIE · doi:10.1007/s10269-008-0919-y
EGFR-Targeted Therapies in Non-small Cell Lung Cancer
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3_5
EGFR Mutant
Kobayashi, K., & Kagamu, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_10
Self-citation
Supplementary Appendix 1 from Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009
Jankú, F., Berry, D. A., Gong, J., Parsons, H. A., Stewart, D. J., & Kurzrock, R. (2023) · doi:10.1158/1078-0432.22445487
A Comprehensive Review of Targeted Therapies for Skin Cancer
Agrahari, K. A., Barewar, S. S., Bakal, R. L., & Hatwar, P. R. (2025) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2025.v85i7.006

Authors: Sutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y., Tanaka, T., Miyazawa, H., Nagata, M., Kanazawa, M., Hagiwara, K., & Kobayashi, K.
Affiliations: Saitama Medical University (JP)
Corresponding author: Kobayashi, K
ORCID: Sutani, A
Uchida, Y
Koyama, N
Tanaka, T
Miyazawa, H
Hagiwara, K
Kobayashi, K
Venue: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Published: 2006-11-14
Volume: 95
Issue: 11
Pages: 1483-1489
ISSN: 0007-0920 (ISSN-L)
1532-1827
DOI: 10.1038/sj.bjc.6603466
PMC: PMC2360739
OpenAlex: W2069312070
Cited by: 167
References: 20
Citations by year: 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 1 · 2015: 7 · 2014: 11 · 2013: 16 · 2012: 15
FWCI: 14.78
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
www.springer.com/tdm (unspecified)
Locations: British Journal of Cancer (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Ministry of Education, Culture, Sports, Science and Technology
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: gefitinib, non-small cell lung cancer, EGFR mutation, targeted therapy, second-line chemotherapy, response rate, survival, prognostic factors, hepatotoxicity, skin toxicity
MeSH terms: Gefitinib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Quinazolines, Survival Analysis, Polymerase Chain Reaction, Genes, erbB-1, Drug Resistance, Neoplasm, Peptide Nucleic Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks